Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2CG | ISIN: CA1850534027 | Ticker-Symbol: CWY0
Düsseldorf
06.06.25 | 08:13
0,797 Euro
-16,54 % -0,158
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CLEARMIND MEDICINE INC Chart 1 Jahr
5-Tage-Chart
CLEARMIND MEDICINE INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7980,84106.06.

Aktuelle News zur CLEARMIND MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoClearmind Medicine Inc. - 6-K, Report of foreign issuer-
DoClearmind Medicine Inc.: Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment54CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05...
► Artikel lesen
20.05.Clearmind Medicine Inc.: Clearmind Medicine to Host Live Webinar "Gazing Through the Crystal Ball" Featuring Leading Psychedelic Experts2
12.05.Clearmind Medicine Inc. - 6-K, Report of foreign issuer1
12.05.SciSparc Ltd: SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction2
CLEARMIND MEDICINE Aktie jetzt für 0€ handeln
12.05.Clearmind Medicine Inc.: Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction1
25.04.Clearmind Medicine files patent for eating disorder treatment1
25.04.Clearmind Medicine reicht Patent für Behandlung von Essstörungen ein1
25.04.SciSparc und Clearmind reichen Patent für Behandlung von Essstörungen ein1
25.04.SciSparc Ltd: SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders4
25.04.Clearmind Medicine Inc. - 6-K, Report of foreign issuer5
25.04.Clearmind Medicine Inc.: Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders1.267Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and...
► Artikel lesen
23.04.Clearmind Medicine Inc.: Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites103The Company is now preparing for the enrollment of the first patient to receive Clearmind's innovative treatment as part of the trial Vancouver, Canada, April 23, 2025 (GLOBE NEWSWIRE) -- Clearmind...
► Artikel lesen
21.04.Clearmind Medicine Inc.: Clearmind Medicine to Host Live Webinar "Gazing Through the Crystal Ball" Featuring Leading Psychedelic Experts1
17.04.Clearmind Medicine Inc.: Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior392Vancouver, Canada, April 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and...
► Artikel lesen
17.04.Clearmind Medicine Inc. - 6-K, Report of foreign issuer-
16.04.Clearmind Medicine startet Phase I/IIa-Studie zur Behandlung von Alkoholsucht-
16.04.Clearmind Medicine Inc.: Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism126Vancouver, Canada, April 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and...
► Artikel lesen
10.04.Clearmind Medicine Inc.: Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder200Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and...
► Artikel lesen
10.04.Clearmind Medicine Inc. - 6-K, Report of foreign issuer-
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1